SCHEMBL20022962

SCHEMBL20022962

O=C(NCc1ccc(F)cc1)C(=O)OCc1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.58
MAPT P10636 1/20 0.58
L3MBTL1 Q9Y468 1/20 0.58
ALDH1A1 P00352 3/20 0.57
RAB9A P51151 2/20 0.57
PLA2G1B P04054 1/20 0.54
ATG4B Q9Y4P1 1/20 0.54
NPC1 O15118 1/20 0.52
POLB P06746 1/20 0.52
MAOB P27338 1/20 0.52
CYP1A2 P05177 1/20 0.51
CYP2C19 P33261 1/20 0.51
KMT2A Q03164 1/20 0.51
ERAP1 Q9NZ08 1/20 0.51
PTGS2 P35354 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.49
KDM4E B2RXH2 2/20 0.49
HPGD P15428 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20022955 0.91 HTT (0.55) LMNAMAPTL3MBTL1ALDH1A1KMT2A
SCHEMBL20022979 0.86 SRC (0.53) MAPTRAB9APOLBCYP1A2CYP2C19
SCHEMBL20022982 0.86 PLA2G1B (0.59) LMNAMAPTL3MBTL1ALDH1A1RAB9A
SCHEMBL20022977 0.85 SMN1; SMN2 (0.62) LMNAMAPTL3MBTL1ALDH1A1RAB9A
SCHEMBL20022981 0.85 PLAAT3 (0.59) LMNAMAPTL3MBTL1ALDH1A1RAB9A
SCHEMBL3979997 0.85 NR1H4 (0.52) LMNAALDH1A1RAB9ANPC1KMT2A
SCHEMBL20022975 0.85 L3MBTL1 (0.57) MAPTL3MBTL1ALDH1A1POLBKMT2A
SCHEMBL17064147 0.85 PLAU (0.64) LMNAMAPTL3MBTL1ALDH1A1RAB9A
SCHEMBL3434164 0.85 PLAU (0.64) LMNAMAPTL3MBTL1ALDH1A1RAB9A
SCHEMBL20022976 0.83 NPC1 (0.62) LMNAMAPTALDH1A1RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2594563-B1 2-acylaminopropanol-type glucosylceramide synthase inhibitors GENZYME CORP (US) 2018-07-18 EP disclosed
US-20180093981-A1 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors GENZYME CORPORATION 2018-04-05 US disclosed
US-20180093981-A1 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors GENZYME CORPORATION 2018-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180093981-A1 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors ASAH2, GBA1, GAA LMNA 1311/4885MAPT 2401/4885L3MBTL1 3762/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.